Roche snaps up ex-US rights to Sarepta's DMD gene therapy

Roche has bought ex-US rights to Sarepta’s Duchenne muscular dystrophy (DMD) gene therapy in a potential multi-billion dollar deal.

Sarepta rebounds on data for limb-girdle muscular dystrophy ...

FDA says no to Sarepta's golodirsen, blocking bid to expand ...

ICER posts damning report on Sarepta’s Duchenne drug Exondys...

Controversy has dogged Sarepta’s Duchenne muscular dystrophy therapy Exondys 51 since its approval, and it’s not out of the woods yet.

Sarepta DMD gene therapy could improve patients' motor funct...

Sarepta Therapeutics announced potentially game-changing results from its Duchenne muscular dystrophy gene therapy candidate, with a small phase 1 trial showing an improvement in patients’

Sarepta dives deeper into gene therapy

Sarepta Therapeutics has handed $30 million to Lacerta in exchange for a group of gene therapies, including a Pompe disease candidate.